Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 4Cyclophosphamide 4fludarabine 3Nivolumab 3Ipilimumab 3Drug Therapy 3aldesleukin 2Biopsy 2utomilumab 1trastuzumab deruxtecan 1sargramostim 1poly ICLC 1liposomal doxorubicin 1fludarabine phosphate 1erythromycin propionate-N-acetylcysteinate 1enzalutamide 1durvalumab 1brodalumab 1atezolizumab 1advexin 1Sirolimus 1Radiotherapy, Conformal 1Quality of Life 1Psychology, Positive 1Poly I-C 1Patient Reported Outcome Measures 1Observation 1National Cancer Institute (U.S.) 1Molecular Diagnostic Techniques 1Microscopy, Electron 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × Chemoembolization, Therapeutic × Dermatologic × Clear all
NCT01336985 2019-12-17

Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
5 enrolled
DermatologicGastrointestinal

Liver Neoplasms, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡